- The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients
-
Taki S, Tamai H, Ida Y, Shingaki N, Kawashima , Shimizu R, Moribata K, Maekita T, Iguchi M, Kato J, Nakao T, Kitano M
- KMID: 2404722
- Gut Liver.
- 2018 Jan;12(1):86-93.
- doi: 10.5009/gnl17048
BACKGROUND/AIMS: Although daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed... -
- CITED
-
- Close
- SHARE
-
- Close
- Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus
-
Tamai H, Ida Y, Kawashima , Shingaki N, Shimizu R, Moribata K, Nasu T, Maekita T, Iguchi M, Kato J, Nakao T, Kitano M
- KMID: 2412236
- Gut Liver.
- 2017 Jul;11(4):551-558.
- doi: 10.5009/gnl16525
BACKGROUND/AIMS: The present study aimed to evaluate the safety and efficacy of simeprevir-based triple therapy with reduced doses of pegylated interferon (PEG-IFN) and ribavirin for interferon (IFN) ineligible patients, such... -
- CITED
-
- Close
- SHARE
-
- Close
